Brief: Candel Therapeutics Q2 Net Income USD -4.796 Million
14/08/2025 13:05
Aug 14 (Reuters) - Candel Therapeutics Q2 operating expenses USD 11.177 million. Q2 basic EPS USD -0.09 Q2 income from operations USD -11.177 million vs. IBES estimate USD -9.5 million
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec